EndoCyclic Therapeutics

EndoCyclic Therapeutics is a pioneering biopharmaceutical company at the forefront of developing non-hormonal, precision medicine for challenging health issues in oncology and women’s health. We are advancing the first non-hormonal, disease-modifying therapeutic for endometriosis and endometrial cancer, utilizing innovative pH-sensitive peptides that target diseased cells without affecting healthy tissue. Our groundbreaking portfolio also includes therapeutics for colon and cervical cancer, along with the first noninvasive targeted MRI imaging agent for endometriosis and a novel targeted MRI agent for colon cancer, each designed to detect even the smallest lesions early and accurately. Endometriosis affects over 10% of women globally and is the leading cause of infertility and disability among women of reproductive age. Despite its prevalence, it remains the most overlooked women’s health issue. At EndoCyclic Therapeutics, our team of world-class physicians, scientists, and pharma/biotech professionals is committed to addressing this gap by bringing forth new solutions that not only treat but also aim to cure these conditions. Our pH-sensitive peptides are specially designed to respond to the altered pH environments found in tumorous and endometriotic tissues, enabling precise delivery of therapeutics and enhancing diagnostic accuracy. This targeted approach is was enables effective treatment and imaging, greatly reducing the risk of side effects and improving patient outcomes. For more information about how we’re driving change in women’s health and oncology, and bringing awareness to these critical issues, please visit our website at www.endocyclictherapeutics.com.